MIV Therapeutics, a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced the first ever human implantation of a hydroxyapatite coated stent and the launch of the MIVT Pilot Trial.
The MIVT Pilot Trial will evaluate the safety and efficacy of MIVT’s polymer-free nanoscale microporous hydroxyapatite drug-eluting stent for the treatment of single de novo lesions in native coronary arteries.
The first procedure was conducted by Dr. Alexandre Abizaid of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. Dr. Abizaid and Institute Dante Pazzanes of Cardiology are among the world’s foremost experts in conducting clinical trials researching both new and existing drug-eluting stents.
The beginning of human implantation represents the culmination of extensive research and development and a successful animal trial program. Human implantation represents a crucial milestone in MIVT’s strategic plan to develop a new class of polymer-free drug-eluting stents that could provide patients with superior outcomes.
"We are very pleased to announce that our human trials are underway in-line with our previous guidance," said Dr. Mark Landy, President of MIV Therapeutics. "We have worked diligently to create a new, novel technology that we expect will be an excellent alternative for millions of patients around the world suffering from coronary artery disease.
MIV Therapeutics is focused on commercializing the next generation of fully biocompatible coatings for cardiovascular stents and drug delivery systems to treat coronary artery disease, an estimated $6 billion worldwide market. The company's technologies are expected to offer a safer alternative to current drug-eluting stents and hope to solve the issues of late thrombosis.
MIVT’s polymer-free nanoscale microporous hydroxyapatite drug-eluting stent uses the Company’s GenX coronary stent system. The GenX stent is coated with one of MIVT’s proprietary hydroxyapatite polymer-free drug eluting systems that is 700 nanometers thin.